Genmab — Februar 2019
-
Ang jnj-372 var der lidt nyt på inspire i forgårs: The trial nurse did mention that the antibodies do not cross the blood-brain barrier. The onc did mention that Janssen (the trial sponsor) is expanding the study to include an arm that combines the infusion with a South Korean drug lazertinib, which has shown promise for brain mets
-
det syntes jeg nu også - der er rigeligt med røverhistorier i dag også
-
Transplant-Ineligible Myeloma: Daratumumab
. OncLiveTV - https://www.youtube.com/watch?v=fwbC9IUOo80 -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

